Xtalks’ Post

How does the Inflation Reduction Act (IRA) redefine compliance requirements for biopharmaceutical companies? In this XTalks webinar, #SyneosHealth experts Tiffany McCaslin and Peter Zou will explore the IRA regulation changes, the scope of data requirement, and the strategic implications on drug development, pricing and market access. Register here: https://lnkd.in/dxVkJgbb #SyneosHealthLife #WorkHereMattersEverywhere #ClinicalCareers #ClinicalResearch #Clinicalcareers #Technologycareers #innovation #AI

How does the Inflation Reduction Act (IRA) redefine compliance requirements for biopharmaceutical companies? In this @XTalks webinar, our experts @Tiffany McCaslin and @Peter Zou will explore the IRA regulation changes, the scope of data requirement, and the strategic implications on drug development, pricing and market access. Register here:  https://lnkd.in/eaDaZByE #SyneosHealth

Discover how Ingenza Ltd’s inGenius platform is reshaping #DrugDevelopment strategies in our recent webinar with Contract Pharma! In this webinar, Ingenza's Rita Cruz reveals how our platform empowers #pharmaceutical innovators to accelerate research, tackle bottlenecks and optimise outcomes. Curious about the full potential of inGenius? Watch the entire webinar on our website today: https://ow.ly/qVAk50UhzHp #EngineeringBiology

How does the Inflation Reduction Act (IRA) redefine compliance requirements for biopharmaceutical companies? In this XTalks webinar, #SyneosHealth experts Tiffany McCaslin and Peter Zou will explore the IRA regulation changes, the scope of data requirement, and the strategic implications on drug development, pricing and market access. Register here: https://lnkd.in/e-YWkt88 #SyneosHealthLife #WorkHereMattersEverywhere #ClinicalCareers #ClinicalResearch 

Learning to be comfortable, being uncomfortable, applies to the pharmaceutical and biotech sector too. “As biopharmaceutical dealmakers become more comfortable with regulatory uncertainty, we’ve seen dealmakers increasingly focused on deals in the $5 billion to $15 billion range rather than in large-scale transformative M&A. Significant progress in innovation continues and we expect to see continued robust deal activity in late 2024 and into 2025," says Roel Van den Akker. While biopharma dealmaking is robust with increasing transaction volumes, the stability in M&A values reflects strategic considerations, regulatory factors, and a focus on innovation and portfolio optimization. This trend underscores the dynamic nature of the biopharma industry and its ongoing evolution toward enhancing healthcare outcomes through strategic partnerships and acquisition. In a "buy, build or partner world" we are seeing the fastest way to growth and improved outcomes is to partner first with specialized services and buy second when it creates synergy with the core business. More info here: https://lnkd.in/euw7Dhm7 #Innovation #Biopharma #Healthcare #Partnerships

Decentralized clinical trials (DCTs) can improve the patient trial experience, attract more diverse clinical trial participants regardless of where they reside, give greater flexibility, and reduce costs—all to bring safe and effective therapies to market faster. But DCT implementation is not a walk in the park. Here are 6 ways to make DCT implementation easier and enable a successful, patient- and site-centric DCT: Want to know more about how Octalsoft's eClinical suite can help you power your next DCT? Book a demo with us today: https://lnkd.in/dePBnvMa #Octalsoft #ClinicalTrials #ClinicalTrial #PharmaceuticalIndustry #PharmaTech #Pharma #Pharmaceutical #Healthcare #HealthcareIndustry #HealthcareSector #HealthcareInnovation

How does the Inflation Reduction Act (IRA) redefine compliance requirements for biopharmaceutical companies? In this XTalks webinar, #SyneosHealth experts Tiffany McCaslin and Peter Zou will explore the IRA regulation changes, the scope of data requirement, and the strategic implications on drug development, pricing and market access. Register here: https://lnkd.in/gdUqiq8K #SyneosHealthLife #WorkHereMattersEverywhere #ClinicalCareers #ClinicalResearch 

𝗙𝗜𝗡𝗔𝗟 𝗖𝗔𝗟𝗟: "𝗥𝗲𝘃𝗼𝗹𝘂𝘁𝗶𝗼𝗻𝗶𝘇𝗶𝗻𝗴 𝗣𝗵𝗮𝗿𝗺𝗮" 𝘄𝗲𝗯𝗶𝗻𝗮𝗿 𝘀𝘁𝗮𝗿𝘁𝘀 𝗶𝗻 𝗮 𝗳𝗲𝘄 𝗵𝗼𝘂𝗿𝘀! This is your last chance to register for our highly anticipated webinar, "𝗥𝗲𝘃𝗼𝗹𝘂𝘁𝗶𝗼𝗻𝗶𝘇𝗶𝗻𝗴 𝗣𝗵𝗮𝗿𝗺𝗮: 𝗧𝗵𝗲 𝗜𝗺𝗽𝗮𝗰𝘁 𝗼𝗳 𝗠𝗼𝗱𝗲𝗿𝗻 𝗗𝗮𝘁𝗮 𝗘𝗻𝗴𝗶𝗻𝗲𝗲𝗿𝗶𝗻𝗴 𝗶𝗻 𝗣𝗵𝗮𝗿𝗺𝗮"—which is about to go LIVE. 🕒 𝟱 𝗽𝗺 𝗖𝗘𝗧 | 𝟭𝟭 𝗮𝗺 𝗘𝗧 | 𝟴 𝗮𝗺 𝗣𝗗𝗧 Get ready to explore the groundbreaking advancements reshaping the pharmaceutical industry. From actionable insights to future strategies, this is your gateway to staying ahead in the evolving pharmaceutical landscape. The seats are almost gone. Secure your spot NOW! 🔗 Registration Link: https://lnkd.in/g_JtUiAk #revolutionizingpharma #dataengineering #pharmaceuticalinnovation #modernpharma #pharmatech #futureofpharma #pharmaceuticalindustry #pharmadata #healthtech #digitaltransformation

Here is 4Cs Head of R&D Outsourcing, Rob Aitchison urging us to embrace innovative approaches and talking about how we can improve and develop the outsourcing model in the pharmaceutical industry as now is the time for change. Please read the article linked in the comments below 👇: A Radical Rethink of the Clinical Outsourcing Model and Approach, let us know your thoughts and get involved. Will Sillar 4C Life Sciences   #pharma #clinicaldevelopment #outsourcing #innovation #industryinsights #lifesciences #Clinicalsourcing

2024 - what a year! 🤩 We’ve achieved some incredible milestones, from award wins to launching Prime Solutions Lab 🌟 But what are our biggest highlights of 2024 and what will 2025 look like for the pharmaceutical industry? We've added some thoughts and insights on this to our ‘year-end review’ article. The topics covered include: ✅ Prime’s 2024 successes ✅ AI’s role in shaping the industry ✅ The impact of US elections on pharma ✅ The increase of integrated solutions in 2025 Read more: https://lnkd.in/dME_Zcu6 #Pharma #IntegratedSolutions #Prime #Healthcare